Data Bridge Market Research analyses that the market is growing with a CAGR of 4.8% in the forecast period of 2023 to 2030 and is expected to reach USD 11,034,329.04 thousand by 2030.

During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 9.50%, primarily driven by rising consumer awareness about healthy lifestyles

"Key Optic Neuritis Therapies Include Efgartigimod Alfa, OCS-05 IV Administration, Ravulizumab, B001, Inebilizumab, Divozilimab, MIL62, Satralizumab, Batoclimab, and More"